share_log

Cantor Fitzgerald Reiterates Overweight on BioVie, Maintains $11 Price Target

Benzinga ·  Jul 18, 2023 20:41

Cantor Fitzgerald analyst Charles Duncan reiterates BioVie (NASDAQ:BIVI) with a Overweight and maintains $11 price target.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment